NCT05093972View on ClinicalTrials.gov

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

April 7, 2026

Primary Completion Date

September 10, 2026

Study Completion Date

September 10, 2026

Conditions

Hepatic Insufficiency

Interventions

DRUG

Ulonivirine

Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY